MDK-0264 Tyrosine kinase inhibitor

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：MDK-0264 Tyrosine kinase inhibitor	Purity：98% min
CAS NO：1021950-26-4	Solubility：DMSO : ≥ 46 mg/mL (78.42 mM)
Molecular Formula：C₃₁H₃₁FN₆O₅	Package：Package according to customer requirements
Molecular Weight：586.613	Storage：Store at -20℃

Quality control

Remarks

MDK-0264, also known as B-Raf IN, B-Raf Inhibitor and Tyrosine kinase inhibitor, is a novel potent tyrosine kinase inhibitor (TKI). MDK-0264 has CAS#1021950-26-4. For the convenience of communication, we temporally name it as MDK-0264

Synonyms:

(3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one;

Related Products:

Capmatinib; MK-8033; Merestinib; SGX-523; Tepotinib; NPS-1034; WYE-125132; PHA-665752; SCR-1481B1; SU11606

References

[1]. Inoue T, et al. Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. World J Surg Oncol. 2012 Aug 20;10(1):167.

[2]. Bowen JM, et al. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther. 2012 Nov 1;13(13).

[3]. Sun FK, et al. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma. Chin Med J (Engl). 2012 Jun;125(12):2231-4.